Concurrent cisplatin-based chemoradiation and adjuvant hysterectomy for bulky stage IB-IIA cervical cancer.
No Thumbnail Available
Date
2005-10-08
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
OBJECTIVES: To evaluate the outcomes and adverse effects of concurrent cisplatin-based chemoradiation and adjuvant hysterectomy for bulky stage IB-IIA cervical cancer MATERIAL AND METHOD: All eligible, thirty-four patients with bulky stage IB-IIA cervical cancer were assigned to receive weekly cisplatin 40 mg/m2 for 6 cycles concurrently with radiation followed by extrafascial hysterectomy 6 weeks after completion of radiation.
RESULTS: Estimated 5-year progression-free and disease-free survival rates of 80% were observed after a median follow-up of 42 months. The overall recurrent rate was 18%. Grade 3 neutropenia and anemia were noted in only 5.9% and 2.9%, respectively. All acute toxicities were transient and were manageable. There were no treatment-related deaths or late toxicities.
CONCLUSION: For appropriately selected patients with bulky stage IB-IIA cervical cancer, concurrent cisplatin-based chemoradiation followed by adjuvant hysterectomy offers an effective treatment option with acceptable toxicity.
Description
Chotmaihet Thangphaet.
Keywords
Citation
Cheewakriangkrai C, Srisomboon J, Chitapanarux I, Suprasert P, Phongnarisorn C, Siriaree S, Charoenkwan K. Concurrent cisplatin-based chemoradiation and adjuvant hysterectomy for bulky stage IB-IIA cervical cancer. Journal of the Medical Association of Thailand. 2005 Oct; 88(10): 1331-7